Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols

European Journal of Nuclear Medicine

Volumn 24, Issue 1, 1997, Pages 35-41

  Bax, J J ^a,b   Veening, M A ^a   Visser, F C ^a   Van Lingen, A ^a   Heine, R J ^a   Cornel, J H ^a   Visser, C A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fluorine 18 fluorodeoxyglucose; Myocardial viability; Single photon emission computed tomography

Indexed keywords

ACIPIMOX; FLUORODEOXYGLUCOSE F 18; NICOTINIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLLIMATOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG CLEARANCE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HEART MUSCLE; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; CORONARY DISEASE; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HEART; HUMANS; MALE; MIDDLE AGED; PYRAZINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030940547     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01728306     Document Type: Article

References (22)

1. Schwaiger M, Hicks R. The clinical role of metabolic imaging of the heart by positron emission tomography. J Nucl Med 1991; 32: 565-578.
2. Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994; 35 (Suppl): 8S-14S.
3. 18F-fluorodeoxyglucose using single photo emission computed tomography. Eur Heart J 1993; 14: 1675-1682.
4. Bax JJ, Visser FC, van Lingen A, et al. Relation between myocardial uptake of thallium-201 chloride and F18-fluorodeoxyglucose imaged with SPECT in normal volunteers. Eur J Nucl Med 1995; 22: 56-60.
5. Martin WH, Delbeke D, Patton JA, et al. FDG-SPECT: correlation with FDG-PET. J Nucl Med 1995; 36: 988-995.
6. Burt RW, Perkins OW, Oppenheim BE, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for the detection of myocardial via-bility. J Nucl Med 1995; 36: 176-179.
7. Bax JJ, Cornel JH, Visser FC, et al. Quantitative analysis of FDG and Tl-201 SPECT for the prediction of functional outcome after revascularization [abstract]. J Nucl Med 1995; 36: 36P.
8. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994; 35: 707-715.
9. Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose. J Nucl Cardiol 1994; 1: S4-S14.
10. Knuuti MJ, Nuutili P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992; 1255-1262.
11. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994; 35: 989-998.
12. Melin JA, Becker LC. Quantitative relationship between global left ventricular thallium uptake and blood flow: effects of propranolol, ouabain, dipyridamole and coronary artery occlusion. J Nucl Med 1986; 27: 641-652.
13. 18F]2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism. J Nucl Med 1978; 19: 1311-1319.
14. 18F-2-deoxy-2-fluoro-D-glueose. J Nucl Med 1978; 19: 1154-1161.
15. Van Lingen A, Huijgens PC, Visser VC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med 1992; 19: 315-321.
16. Lee KS, vom Dahl J, Hicks RJ, Schwaiger M. Relationship between blood glucose levels and F-18 fluorodeoxyglucose image quality in cardiac PET FDG studies [abstract]. J Am Coll Cardiol 1991; 17: 120A.
17. Vom Dahl J, Hermann WH, Hicks RJ, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed by positron emission tomography. Circulation 1993; 395-404.
18. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995; 36: 456-463.
19. Nuutili P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992; 89: 1767-1774.
20. Musatti L, Maggi E, Moro E, et al. Bioavailability and pharmacokinetics of Acipimox, a new antilipolytic and hypolipidaemic agent. J Int Med Res 1981; 381-386.
21. 18F-FDG in myocardium and femoral muscle as assessed by planar imaging. Eur J Nucl Med 1995; 22: 1141-1148.
22. 18F-fluorodeoxyglucose imaged with positron emission tomography and single photon emission computed tomography in dyssynergic myocardium. J Nucl Med 1996; in press.